このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

喘息の小児(6歳から12歳未満)におけるグリコピロニウム(臭化物)の薬物動態、薬力学、安全性および忍容性

2026年11月9日 更新者:Novartis Pharmaceuticals

グリコピロニウム(臭化物) 6 歳から 12 歳未満の喘息の子供に。

The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 12 years old with moderate to severe asthma.

調査の概要

詳細な説明

The study design is a double-blind, placebo controlled, randomized sequence, three-treatment, three-period, six-sequence, cross-over multiple-dose study to evaluate efficacy, pharmacokinetics, pharmacodynamics, and safety and tolerability of glycopyrronium bromide (bromide) in children from 6 to less than 12 years of age with asthma with forced expiratory volume in one second (FEV1) ≥60% and ≤ 90% of the predicted normal value for the participant.

This study will consist of 4 phases: Screening, Run-in, Treatment and Follow-up.

After the screening phase, participants will enter the Run-in Phase to further assess eligibility and those participants that meet all eligibility criteria will be randomized. Study treatment will be administered in addition to background asthma LABA+ICS controller therapy (salmeterol xinafoate 50µg/fluticasone propionate 100µg) from entering the run-in period, through to the end of the treatment phase, including the 2 wash-out periods. Participants will be randomized to one of 6 different sequences with an equal (1:1:1:1:1:1) randomization ratio. The Treatment Phase will last 10 weeks, and every sequence is divided in three treatment periods: Glycopyrronium bromide 12.5 µg, Glycopyrronium bromide 25µg or matching placebo dry powder in capsules for inhalation, via Breezhaler. Each treatment period lasts 2 weeks and 2 consecutive treatment periods are separated by a 2-week wash-out period. Participants who discontinue their study treatment prematurely will be required to return to the clinic for an Early Termination Visit. 30 days after last treatment date, a final telephone contact must be conducted for safety follow-up.

The total duration of the trial for a participant (from screening to follow up) is approximately 20 weeks including safety follow-up.

研究の種類

介入

入学 (推定)

42

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Novartis Pharmaceuticals

研究場所

      • London、イギリス、SE5 9RS
        • 募集
        • Novartis Investigative Site
      • Stoke-on-Trent、イギリス、ST4 6QG
        • 募集
        • Novartis Investigative Site
      • Guatemala City、グアテマラ、01015
        • 募集
        • Novartis Investigative Site
    • GTM
      • Guatemala City、GTM、グアテマラ、01010
        • 引きこもった
        • Novartis Investigative Site
    • Tolima Department
      • Ibague、Tolima Department、コロンビア、730006
        • 募集
        • Novartis Investigative Site
      • Barcelona、スペイン、08035
        • 募集
        • Novartis Investigative Site
    • Barcelona
      • Esplugues、Barcelona、スペイン、08950
        • 募集
        • Novartis Investigative Site
      • Sabadell、Barcelona、スペイン、08208
        • 募集
        • Novartis Investigative Site
    • Extremadura
      • Mérida、Extremadura、スペイン、06800
        • 引きこもった
        • Novartis Investigative Site
      • Budapest、ハンガリー、1083
        • 募集
        • Novartis Investigative Site
      • Budapest、ハンガリー、1033
        • 募集
        • Novartis Investigative Site
      • Eger、ハンガリー、3300
        • 募集
        • Novartis Investigative Site
      • Kaposvár、ハンガリー、7400
        • 引きこもった
        • Novartis Investigative Site
      • Nagykanizsa、ハンガリー、8800
        • 引きこもった
        • Novartis Investigative Site
      • Szigetvár、ハンガリー、7900
        • 募集
        • Novartis Investigative Site
    • Hajdu Bihar Megye
      • Debrecen、Hajdu Bihar Megye、ハンガリー、4032
        • 募集
        • Novartis Investigative Site
      • Rousse、ブルガリア、7002
        • 募集
        • Novartis Investigative Site
      • Sevlievo、ブルガリア、5400
        • 募集
        • Novartis Investigative Site
      • Sofia、ブルガリア、1510
        • 募集
        • Novartis Investigative Site
    • Poland
      • Tarnów、Poland、ポーランド、33-100
        • 募集
        • Novartis Investigative Site
    • Łódź Voivodeship
      • Lodz、Łódź Voivodeship、ポーランド、90-329
        • 募集
        • Novartis Investigative Site
      • Cape Town、南アフリカ、7531
        • 募集
        • Novartis Investigative Site
    • Western Cape
      • George、Western Cape、南アフリカ、6529
        • 募集
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6年~11年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Confirmed diagnosis of asthma for at least 6 months
  • Signed informed consent by parent(s)/legal guardian(s) and assent by the pediatric participant (depending on local requirements)
  • Participant on stable dose of inhaled low-to-medium dose ICS with one additional controller for at least 4 weeks prior to run-in
  • Pre-Bronchodilator FEV1 ≥60% to ≤90% of predicted normal at beginning of Run-in and randomization. If FEV1 eligibility criteria are not met at -45min pre-dose of the End of Run-in (Visit 30), the visit can be rescheduled once within 5 days from the previous attempt.
  • FEV1 reversibility, done using up to 4 puffs of SABA (up to 400μg salbutamol or 360μg albuterol) at Run-in visit (Visit 20): increase > and/or = 12% (performed according to American Thoracic Society (ATS)/European Respiratory Society (ERS) 2019 guidelines). All participants must perform a reversibility test at start of Run-in. If reversibility is not demonstrated at Run-in, it may be attempted at up to two ad hoc, unscheduled separate visits within 5 days from previous attempt. If reversibility is still not demonstrated after repeated assessment participants must be screen failed
  • Demonstrated acceptable inhaler use technique for Diskus/Accuhaler (prior to run-in) and Breezhaler (prior to randomization) and able to complete spirometry procedures prior to randomization.
  • A parent/legal guardian must be designated to complete all e-Diary entries and attend all clinic visits with the participant.
  • Parents/legal guardian must be willing and able to assist the child with the procedures outlined in the protocol, e.g. compliance with study medication, completion of electronic participant diary
  • Female participants of child-bearing potential, who might become sexually active, must be informed of the need to prevent pregnancy during the study using effective contraceptive methods. The decision on the contraceptive method should be reviewed at least every 3 months to evaluate the individual need and compatibility of the method chosen.

Exclusion Criteria:

  • Systemic corticosteroid use for any reason within 3 months of Run-in
  • Participants on low to medium mono ICS alone
  • Participants requiring six or more puffs of rescue medication per day on more than two consecutive days in the four weeks prior to Screening (Visit 1) and/or in the four weeks prior to the Run-in visit
  • Participants who have had an asthma attack/exacerbation requiring a) systemic corticosteroids (SCS) or b) hospitalization or c) emergency room visit, within 3 months prior to Screening (Visit 1), or more than 3 separate exacerbations in the 12 months preceding the Screening visit
  • Participants with a known narrow-angle glaucoma, bladder dysfunction, bladder outlet obstruction or any other conditions where anticholinergic treatment is contraindicated prior to Screening (Visit 1)
  • Participants with a history of long QT syndrome or whose corrected QT interval (QTc) measured at start of Run-in and confirmed at Baseline (prior to randomization) (Fridericia method) is prolonged (> 450 msec for boys and girls) and confirmed by a central assessor (these patients should not be rescreened)
  • Suspected or documented active infections (bacterial, viral, fungal, mycobacterial or other, including active SARS-CoV-2, tuberculosis or atypical mycobacterial disease) of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 6 weeks of Screening (Visit 1)
  • History of Type I diabetes or uncontrolled Type II diabetes
  • Participants who are sexually active at screening
  • Hemoglobin levels outside normal ranges at Run-in (Visit 20)
  • Female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if they become sexually active during study participation, do not agree to the use of contraception as defined in the inclusion criteria.

Additional protocol-defined inclusion / exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Glycopyrronium 25μg

Glycopyrronium 25μg for two weeks

25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

他の名前:
  • NVA237

Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

他の名前:
  • NVA237
実験的:Glycopyrronium 12.5μg

Glycopyrronium 12.5μg for two weeks

25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

他の名前:
  • NVA237

Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

他の名前:
  • NVA237
プラセボコンパレーター:Placebo

Placebo for two weeks

25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

他の名前:
  • NVA237

Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

他の名前:
  • NVA237

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in trough FEV1
時間枠:At the start and end of each 2 week treatment period (Days 1, 14, 29, 42, 57 and 70)

Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.

At the start and end of each 2 week treatment period (Days 1, 14, 29, 42, 57 and 70)

二次結果の測定

結果測定
メジャーの説明
時間枠
Steady state pharmacokinetic (PK) parameters C0
時間枠:At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)

Steady state pharmacokinetic (PK) parameters C0 will be provided for plasma glycopyrronium concentrations at pre-dose and post-dose time-points.

At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)
Systemic exposure following sparse PK sampling
時間枠:At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)

Systemic exposure following sparse PK sampling will be provided at pre-dose and post-dose time-points for each glycopyrronium dose level

At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)
Change from Baseline in PEF rate
時間枠:At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)

Morning and Evening Peak Expiratory Flow Rate (PEF) will be measured. PEF is the peak expiratory flow, the maximum speed of expiration.

At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)
Change from Baseline in FEV1
時間枠:At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)

Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.

At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)
Change from baseline in rescue medication use
時間枠:At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)

Daily use of rescue medication will be recorded each morning and evening throughout the 2 week treatment by the participant using their electronic diary.

At the start and end of each 2 week treatment period (Days 1, 14, 15, 29, 42, 43, 57, 70 and 71)
Adverse events of special interest (AESI) typical of anti-muscarinic side effects
時間枠:From the start of run-in to 30 days after end of treatment, assessed up to maximum duration of 16 weeks

AESIs that are typical of anti-muscarinic agents will be reported.

From the start of run-in to 30 days after end of treatment, assessed up to maximum duration of 16 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年8月29日

一次修了 (推定)

2027年7月30日

研究の完了 (推定)

2027年8月30日

試験登録日

最初に提出

2022年1月10日

QC基準を満たした最初の提出物

2022年1月24日

最初の投稿 (実際)

2022年2月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する